T細胞療法市場－全球產業規模、佔有率、趨勢、機會和預測，依療法類型、適應症（血液系統惡性腫瘤、實體腫瘤及其他）、地區和競爭格局分類，2020-2030年預測

2024年全球T細胞療法市場規模為29.2億美元，預計2030年將以9.9%的複合年成長率成長至51.4億美元。 T細胞療法是一種特殊的免疫療法，它透過改造患者自身的T細胞，增強其識別和清除病變細胞（主要是癌細胞）的能力。全球癌症發生率的不斷上升、基因工程技術的持續進步以及對新型免疫療法研發的大量投資，都顯著推動了該市場的成長。

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球T細胞療法市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依治療類型（CAR T 細胞療法、基於 T 細胞受體 (TCR) 的療法、基於腫瘤浸潤淋巴細胞 (TIL) 的療法）
  • 按適應症（血液系統惡性腫瘤、實體腫瘤、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美T細胞療法市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲T細胞療法市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區T細胞療法市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲T細胞療法市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲T細胞療法市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購（如有）
• 產品發布（如有）
• 最新進展

第13章：全球T細胞療法市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Novartis AG
• Merck KGaA
• Gilead Sciences Inc.
• TCR2 Therapeutics Inc
• Bluebird Bio Inc.
• Sorrento Therapeutics Inc.
• Fate Therapeutics Inc.
• Pfizer Inc.
• Amgen Inc
• Celgene Corporation

第16章：策略建議

第17章調查會社について,免責事項

The Global T-cell Therapy Market, valued at USD 2.92 Billion in 2024, is projected to experience a CAGR of 9.9% to reach USD 5.14 Billion by 2030. T-cell therapy represents a specialized form of immunotherapy that involves modifying a patient's own T-cells to enhance their ability to identify and eliminate diseased cells, primarily cancerous ones. The market's expansion is significantly propelled by the increasing global prevalence of various cancers, continuous technological advancements in genetic engineering techniques, and substantial investments directed towards research and development for novel immunotherapeutic approaches.

Key Market Drivers

The escalating global burden of cancer presents a substantial and persistent demand driver for innovative therapeutic solutions, including T-cell therapy. The increasing incidence of various cancer types globally necessitates the continuous development and adoption of advanced treatment modalities that offer improved efficacy and patient outcomes, particularly for those refractory to conventional therapies. This pressing medical need directly fuels investment and research into T-cell therapies, positioning them as critical options in oncology. According to the American Cancer Society and the International Agency for Research on Cancer, April 2024, Global Cancer Statistics 2024, close to 20 million cancer cases were newly diagnosed in 2022 around the world, underscoring the vast and growing patient population requiring novel interventions.

Key Market Challenges

The inherently high cost associated with personalized T-cell therapies, driven by complex and resource-intensive manufacturing processes, presents a significant impediment to market expansion. These treatments necessitate individual modification of a patient's own T-cells, leading to high production expenses. This directly restricts widespread patient access and imposes considerable financial pressure on healthcare systems and payers globally. Consequently, the adoption rate of these innovative therapies is constrained, preventing broader market penetration despite their demonstrated clinical efficacy.

Key Market Trends

The shift towards allogeneic T-cell therapies represents a significant evolutionary step in the global T-cell therapy market, moving away from individualized autologous treatments which rely on a patient's own cells. This transition aims to address the inherent manufacturing complexities and high costs associated with personalized therapies, paving the way for more readily available, "off-the-shelf" products. These allogeneic platforms, utilizing donor cells, hold the potential to enhance scalability and accessibility, thereby broadening the eligible patient population. According to the Alliance for Regenerative Medicine, in January 2024, the sector anticipated the potential for the first United States approval of an allogeneic T-cell therapy that year.

Key Market Players

• Novartis AG
• Merck KGaA
• Gilead Sciences Inc.
• TCR2 Therapeutics Inc
• Bluebird Bio Inc.
• Sorrento Therapeutics Inc.
• Fate Therapeutics Inc.
• Pfizer Inc.
• Amgen Inc
• Celgene Corporation

Report Scope:

In this report, the Global T-cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

T-cell Therapy Market, By Therapy Type:

• CAR T-cell Therapy
• T Cell Receptor (TCR)-based
• Tumor Infiltrating Lymphocytes (TIL)-based)

T-cell Therapy Market, By Indication:

• Hematologic Malignancies
• Solid Tumors
• Others

T-cell Therapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global T-cell Therapy Market.

Available Customizations:

Global T-cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global T-cell Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (CAR T-cell Therapy, T Cell Receptor (TCR)-based, Tumor Infiltrating Lymphocytes (TIL)-based))
  • 5.2.2. By Indication (Hematologic Malignancies, Solid Tumors, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America T-cell Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Indication
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States T-cell Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Indication
  • 6.3.2. Canada T-cell Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Indication
  • 6.3.3. Mexico T-cell Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Indication

7. Europe T-cell Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Indication
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany T-cell Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Indication
  • 7.3.2. France T-cell Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Indication
  • 7.3.3. United Kingdom T-cell Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Indication
  • 7.3.4. Italy T-cell Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Indication
  • 7.3.5. Spain T-cell Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Indication

8. Asia Pacific T-cell Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Indication
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China T-cell Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Indication
  • 8.3.2. India T-cell Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Indication
  • 8.3.3. Japan T-cell Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Indication
  • 8.3.4. South Korea T-cell Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Indication
  • 8.3.5. Australia T-cell Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Indication

9. Middle East & Africa T-cell Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Indication
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia T-cell Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Indication
  • 9.3.2. UAE T-cell Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Indication
  • 9.3.3. South Africa T-cell Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Indication

10. South America T-cell Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By Indication
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil T-cell Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Indication
  • 10.3.2. Colombia T-cell Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Indication
  • 10.3.3. Argentina T-cell Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Indication

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global T-cell Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Gilead Sciences Inc.
• 15.4. TCR2 Therapeutics Inc
• 15.5. Bluebird Bio Inc.
• 15.6. Sorrento Therapeutics Inc.
• 15.7. Fate Therapeutics Inc.
• 15.8. Pfizer Inc.
• 15.9. Amgen Inc
• 15.10. Celgene Corporation

16. Strategic Recommendations

17. About Us & Disclaimer